Arthritis Pain Management Market Size, Share and Forecast 2019-2025Posted by nabeel on January 29th, 2021 The global arthritis pain management market is projected to exhibit considerable growth during the forecast period (2019-2025). The high prevalence of this arthritis disorder, the rapid increase in the R&D activities related to the drug development process for the treatment of this disorder by the key players operating is a major factor anticipated to fuel the arthritis pain management market during the forecast period. Johnson & Johnson Services Inc., F. Hoffman La Roche, Merck & Co. Inc., Sanofi SA, Pfizer Inc., Abbvie, Inc., Allergen PLC, Bayer AG, Amgen Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc, Bristol-Myers Squibb, Eli Lilly and Co., Endo Pharmaceutical, Inc., and so on are the key market players operating in the global arthritis pain management industry. Get Free Sample Copy @ https://www.omrglobal.com/request-sample/arthritis-pain-management-market These market players are making a hefty investment in their R&D sector to perform drug development for the launch of new and advanced drugs for the treatment of this disorder. For instance, in February 2020, GlaxoSmithKline Plc received FDA approval fordiclofenac sodium topical gel, 1% (Voltaren Arthritis Pain, GlaxoSmithKline) for temporary relief of arthritis pain. further, in June 2019, Eli Lili & Co. received FDA approval for baricitinib (Olumiant), used to get relief from arthritis pain. Baricitinib is a targeted disease-modifying antirheumatic drug (DMARD) that blocks Janus kinase (JAK), a group of enzymes that enable inflammatory signals to be activated inside a cell. In June 2017, Regeneron Pharmaceuticals, Inc., and Sanofi S.A. received FDA approval for Kevzara (sarilumab) injection to treat adults with moderate to severe rheumatoid arthritis (RA). Kevzara, a human monoclonal antibody that binds to the interleukin-6 receptor (IL-6R), may be used as monotherapy or in combination with MTX or other DMARDs. This drug is given to the patient who had an inadequate response or intolerance to methotrexate (MTX-IR) drug. Thus, the increasing FDA approval for the drugs and therapy for the treatment of arthritis is anticipated to be a major factor to drive the growth of the global arthritis pain management market. Current Market Trends Covered in the Market Report.
Global Arthritis Pain Management Market Segmentation By Drug Type
By End-User
Global Arthritis Pain Management Market Segmentation by region North America
Europe
Asia-Pacific
Rest of the World
Reasons to Buying From us – 1. We cover more than 15 major industries, further segmented into more than 90 sectors. 2. More than 120 countries are for analysis. 3. Over 100+ paid data sources mined for investigation. 4. Our expert research analysts answer all your questions before and after purchasing your report. For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/arthritis-pain-management-market About Orion Market Research Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. Media Contact: Company Name: Orion Market Research Contact Person: Mr. Anurag Tiwari Email: info@omrglobal.com Contact no: +91 780-304-0404 Like it? Share it!More by this author |